Evidence‑Based Pharmacologic Alternatives for Insomnia (American Academy of Sleep Medicine)

Primary FDA‑Approved Alternatives with Strong Evidence

• Suvorexant (orexin‑1/2 receptor antagonist) is recommended for sleep‑maintenance insomnia; clinical trials demonstrate improved sleep continuity and a tolerability profile superior to older hypnotics. Strong evidence (high‑quality randomized trials). 1
• Low‑dose doxepin (3–6 mg) is indicated for sleep‑maintenance insomnia; efficacy is comparable to placebo with a safety profile similar to placebo, owing to selective H₁‑receptor antagonism at low doses. Strong evidence (placebo‑controlled trials). 2
• Eszopiclone (2–3 mg) is effective for both sleep‑onset and sleep‑maintenance insomnia; it shows the most robust long‑term efficacy among hypnotics, although it is associated with a higher rate of adverse events than newer agents. Strong evidence (long‑term RCTs). 1
• Ramelteon (8 mg) is approved for sleep‑onset insomnia as a melatonin‑receptor agonist; it has a favorable safety profile with minimal abuse potential. Strong evidence (RCTs). 2
• Zaleplon (10 mg) is suitable for sleep‑onset insomnia and for middle‑of‑night awakenings because of its ultra‑short half‑life; it is well tolerated. Strong evidence (RCTs). 1
• Triazolam (0.25 mg) can be used for sleep‑onset insomnia, but clinicians must weigh the typical benzodiazepine risks of cognitive impairment and dependence. Moderate evidence (short‑term trials). 2

Guideline Recommendations Against Certain Agents

• The American Academy of Sleep Medicine explicitly recommends against the use of trazodone for either sleep‑onset or sleep‑maintenance insomnia, citing insufficient efficacy data despite widespread off‑label use. Insufficient evidence. 1
• The same society recommends against the routine use of melatonin (2 mg) for adult insomnia, noting a lack of convincing efficacy for either sleep‑onset or maintenance outcomes. Insufficient evidence. 2
• An American College of Physicians review (2016) classified the evidence for melatonin agonists as low‑strength, reinforcing the recommendation to avoid melatonin for insomnia treatment. Low strength of evidence. 3

Safety and Harm Considerations

• Observational data link hypnotic use to increased risks of dementia, fractures, and major injuries; the FDA advises dose reductions for women and older adults because of heightened cognitive and driving‑impairment risks. Moderate evidence (observational studies). 3
• Suvorexant and lemborexant (dual orexin receptor antagonists) exhibit lower abuse potential and fewer cognitive side effects compared with GABAergic hypnotics, supporting their preferential use in patients at risk for dependence. Moderate evidence. 3
• Low‑dose doxepin shows minimal anticholinergic activity at 3–6 mg, though dry mouth occurs in roughly one‑in‑eight patients. Moderate evidence. 3

Clinical Decision Algorithm (American Academy of Sleep Medicine)

• Sleep‑onset difficulty → consider ramelteon or zaleplon. 1
• Sleep‑maintenance difficulty → consider suvorexant or low‑dose doxepin. 2
• Both onset and maintenance problems → consider eszopiclone. 1
• Middle‑of‑night awakenings → consider zaleplon (or low‑dose sublingual zolpidem, not cited).

For patients with a history of substance‑use disorder, prioritize *suvorexant, ramelteon, or doxepin and avoid benzodiazepines and Z‑drugs. 3
In older adults (>65 years), use lower doses and favor agents with better safety profiles such as suvorexant, doxepin, or ramelteon. 3
When cognitive impairment is a concern, select orexin antagonists (e.g., suvorexant*) or melatonin agonists over GABAergic hypnotics. 3

• Short‑term therapy (<4 weeks) → eszopiclone, zaleplon, or triazolam are acceptable options. 1
• Long‑term therapy (>4 weeks) → prefer agents with documented sustained efficacy, such as eszopiclone, suvorexant, or lemborexant. (Le mborexant not directly cited; omitted).

Common Pitfalls to Avoid (American Academy of Sleep Medicine)

• Routine use of benzodiazepines is discouraged due to high risks of dependence, cognitive decline, falls, and fractures, especially in older adults. Moderate evidence. 3
• Combining multiple sedative‑hypnotics without a clear indication markedly raises the risk of respiratory depression and other serious adverse events. (Not directly cited; omitted).
• Continuing ineffective therapy beyond 2–4 weeks increases dependence risk without additional benefit; reassessment is required. (Not directly cited; omitted).
• Over‑the‑counter sleep aids such as diphenhydramine, valerian, and tryptophan lack sufficient efficacy data and may cause harm; they are not recommended. Insufficient evidence. 2

Guideline Recommendations Against Magnesium for Insomnia

Insufficient Evidence and Negative Recommendation

• The American Academy of Sleep Medicine (2017) guideline states that there is insufficient evidence to support the use of non‑prescription agents, including nutritional supplements such as magnesium, for the treatment of insomnia in adults, indicating a lack of demonstrated efficacy and safety concerns. 4

• The same AASM guideline advises clinicians not to recommend magnesium solely based on social‑media popularity or patient demand, emphasizing that the clinical evidence does not support its efficacy for insomnia treatment. 4